FDA Authorizes Marketing of Device That Can Improve Gait in Multiple Sclerosis Patients

FDA is taking an initiative to authorize the marketing of Portable Neuromodulation Stimulator (PoNS) for Multiple Sclerosis patients which can help patients with their motor deficit to some extent.

Are you aware of the condition called Multiple Sclerosis? This is one of the leading causes of neurological disability in many patients worldwide. It basically affects the nerve lining sheath. When this nerve sheath gets worn out, it results in electric shock, and pain may affecting their functions like talking, walking, and writing. Just imagine, the outer covering of the nerve sheath gets worms out causing intense damage to the actual nerve. It can get really painful and affect your walking and speech as the communication between the brain and body is carried by nerves. In the end, the nervous system gets disrupted resulting in slow walking and delayed speech. As age advances, the person suffering from Multiple Sclerosis gets further deteriorated. 

FDA comes to help the patients with Multiple Sclerosis

On 26th March 2021, the Food and Drug Administration (FDA) authorized the marketing of a device that can help patients of Multiple Sclerosis with gait deficit with mild to moderate symptoms. The device is to be used by a prescription only as an adjunct to supervise exercise training programs in patients with Multiple Sclerosis at age 22 or older. The device is called Portable Neuromodulation Stimulator (PoNS) is a neuromuscular stimulator which helps generate electrical impulses or trigeminal and facial nerve via the tongue to provide treatment for motor deficit problems. 

What is Multiple Sclerosis?

Multiple sclerosis is a chronic disease of the central nervous system. It is an autoimmune disorder, a condition in which the body mistakenly attacks its own healthy cells. Multiple Sclerosis is an unpredictable disease that affects people differently. The symptoms may vary from patient to patient and each may depend upon the area of damage. Multiple Sclerosis is the second cause of neurological disease and disability, after trauma. It affects more men than women. 

The real science behind Multiple Sclerosis 

As the name suggests, there is sclerosis or degradation of the outer sheath of the nerve which is also known as the myelin sheath. Myelin sheath is the outer fatty layer of the nerve. This myelin sheath protects the nerve fibers by providing a shield to the actual nerve. In Multiple Sclerosis , the myelin sheath is destroyed in many years affecting their functioning. This loss of myelin forms scar tissue called sclerosis. When the nerves are damaged in this way, they conduct electrical impulses to and from the brain. 

Causes for Multiple Sclerosis 

Autoimmune causes  Infectious agents such as virus  Environmental factors  Genetic factors 

Symptoms of Multiple Sclerosis 

The symptoms of Multiple Sclerosis are unpredictable. They may be mild or severe, short-term or long-lasting. Theory may appear in different combinations, dispensing on the area of the nervous system affected. The following are the most common symptoms of Multiple Sclerosis. But each person may have different symptoms. 

Blurred or double vision Red or green color distortion  Pain or loss of vision because of swelling of the optic nerve  Trouble walking  An abnormal feeling such as numbness or pricking sensation of pins and needles Muscle weakness in arms and legs  Difficulty in coordination while walking and standing  Spasticity: Involuntary increased tone of muscles Stiffness Of muscles Spasm of muscles  Fatigue on physical activity  Constant tiredness that does not go away  Loss of feeling  Speech problems: delayed of slurred speech  Tremors  Dizziness  Hearing loss  Bowel and Bladder problem  Depression  Changes in sexual function  Thinking inability or cognitive function  Difficulty in focus and attention  Memory loss  Poor judgment 

All you need to know about the Portable Neuromodulation Stimulator (PoNS) for Multiple Sclerosis patients 

The FDA assesses the safety and effectiveness of Portable Neuromodulation Stimulator (PoNS) for Multiple Sclerosis patients through 2 clinical studies and retrospective analysis of the Real-World Clinical Data (RWD). The FDA is granted marked authorization of Portable Neuromodulation Stimulator (PoNS) for Multiple Sclerosis patients to Helius Medical Inc. 

Tags : #myhealth #medicircle #FDA #multiplesclerosis #PortableNeuromodulationStimulator

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Cancer on the Menu: How Excess Salt is Quietly Killing Your StomachDecember 03, 2024
Breaking Barriers: Honouring the International Day of Persons with Disabilities December 03, 2024
Invisible Threat: How Air Pollution is Impacting Pregnancies and Shaping Future GenerationsDecember 03, 2024
Medanta Gurugram successfully treats ‘rarest of rare’ lymph node cancer resistant to other drugs using CAR-T Cell TherapyDecember 03, 2024
Nonin Medical secures FDA clearance for its over-the-counter fingertip pulse oximeter, accurate for patients of all skin colorsDecember 02, 2024
ALARM 2024: Amrita Leads the Fight Against Antimicrobial ResistanceDecember 02, 2024
Coral adaptation unlikely to keep pace with global warmingDecember 02, 2024
Reaching the unreached to find missing TB casesDecember 02, 2024
Sip Smart: Why Changing Your Water Habits Can Change Your LifeNovember 28, 2024
Can Your Fingers Predict How Much You Drink? New Study ExplainsNovember 28, 2024
India Leads Global Medical Tourism with 8% Share; PSRI Sets New Benchmarks with nearly 15% International Patient BaseNovember 28, 2024
Medicines save lives but not when they stop workingNovember 28, 2024
A total of 340 Children Participated in the Painting Competition Organized by Asian HospitalNovember 28, 2024
The Standing Desk Myth: Is Sitting Actually Healthier?November 27, 2024
How Cancer Outsmarts Chemotherapy: The Hidden Metabolic GameNovember 27, 2024
Aakash Healthcare Saves life of a 61-year-old Women through Timely Neuro-intervention with a multi-disciplinary management of StrokeNovember 27, 2024
Breakfast Wars: Why Men and Women Should Eat DifferentlyNovember 27, 2024
Only 10% of Businesses Are Ready to Become Experience-Orchestrated, Highlighting Lack of PersonalisationNovember 27, 2024
Investors Think Safe, but Act Bold: MyFi Report Exposes Risk Tolerance Mismatch November 27, 2024
Indkal Technologies Redefines Luxury Home Entertainment with Acer M Series Hybrid MiniLED TelevisionsNovember 27, 2024